CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 6 enrolled
Drug / intervention
Omalizumab +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00367016
NCT00367016Phase 4Completed
CompareCT.gov

Immunologic Basis of Anti-IgE Therapy (Study II: On Patients With Asthma)

University of California, Davis·interventional·Posted Aug 22, 2006·Updated Jul 13, 2021

In Brief

A Phase 4 clinical trial evaluating Omalizumab and Placebo for Asthma and 2 related conditions. Completed, enrolled 6 participants across 1 site.

Detailed Summary

The purpose of this study is to look at measures that will help scientists understand the way Omalizumab, an FDA-approved anti-allergy medication, works.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAsthma, Allergic Rhinitis, Atopic Dermatitis
CountriesUnited States
Collaborators--

Timeline

Phase 4CompletedFinished
200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedAug 22, 2006
Enrollment StartFeb 1, 2004
Primary CompletionOct 17, 2012
TodayJul 2, 2026
Enrollment to primary: 8.7 yearsPosted 19.9 years ago

Interventions

Omalizumabdrug

Xolair (Omalizumab) will be given by subcutaneous injection according to Ige level and weight calculation.

Placebodrug

Placebo, given by subcutaneous injection.